Currently, vaccine candidates for the coronavirus are in various stages of development. Across the world, there are 135 vaccines in preclinical trials and 20 that are being tested on humans.
It’s going to be a major win for the company that can discover a vaccine that works. Not only will it…
have a significant impact on global health but also generate billions of dollars in profits. Not to mention, it will generate trillions of dollars of value for the economy as people around the world are once again able to go to their offices, restaurants, sporting events, movies, etc.
Talk about a win-win.
Therefore, all investors should keep an eye on the latest developments in the race to find a vaccine. Here is the latest on five stocks that are leading this race:
Novavax, Inc. (NVAX)
NVAX was in the news this week as it received $1.6 billion from Operation Warp Speed to complete late-stage clinical development, establish large-scale manufacturing, and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020.
It’s the largest contribution from Operation Warp Speed thus far, and many consider NVAX to be one of the leaders.
The company’s vaccine aims to increase the body’s production of antibodies to block the protein that the coronavirus uses to invade cells. NVAX is expected to report results of its phase 2 trial later this month and begin a final-stage study with 30,000 participants this fall.
How does NVAX stack up for the POWR Ratings?
A for Trade Grade
A for Buy & Hold Grade
A for Industry Rank
A for Peer Grade
A for overall POWR Rating
You can not ask for better. It’s also the 15th ranked stock in the Biotech sector. it is the #1 rated stock in the Biotech sector.
Inovio Pharmaceuticals Inc. (INO)
INO reported positive phase 1 data for its coronavirus vaccine candidate in that it successfully increased the antibody count in participants. After six weeks, 94% of participants had an increased antibody count following two doses.
INO’s vaccine is based on its DNA medicine research, injecting DNA plasmids into the body to create an immune response. Its stock started rallying starting in February as soon as the coronavirus crisis began. In sum, it’s gained 700%.
INO’s POWR Ratings are also strong with a Buy rating. The stock has an “A” for Trade Grade, By & Hold Grade, and Peer Grade. Among biotech stocks, it’s ranked #44 out of 337.
Moderna, Inc. (MRNA)
MRNA is in the midst of its phase 1 trial and their interim data was positive. The company reported that binding and neutralizing antibody counts of participants were at the same level or higher than in patients who had recovered from the coronavirus. Although, it was a small sample size with only 8 participants.
MRNA plans to begin phase 2 trials…
Continue reading at STOCKNEWS.com
